These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9529694)

  • 21. Maladaptive and compulsive behavior in Prader-Willi syndrome: new insights from older adults.
    Dykens EM
    Am J Ment Retard; 2004 Mar; 109(2):142-53. PubMed ID: 15000675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoxetine in pathologic skin-picking: open-label and double-blind results.
    Bloch MR; Elliott M; Thompson H; Koran LM
    Psychosomatics; 2001; 42(4):314-9. PubMed ID: 11496020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine and compulsive sexual behavior.
    Aguirre B
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):943. PubMed ID: 10434484
    [No Abstract]   [Full Text] [Related]  

  • 24. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.
    Bonnot O; Cohen D; Thuilleaux D; Consoli A; Cabal S; Tauber M
    Eur J Pediatr; 2016 Jan; 175(1):9-18. PubMed ID: 26584571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Subtype-Phenotype Analysis of Growth Hormone Treatment on Psychiatric Behavior in Prader-Willi Syndrome.
    Montes AS; Osann KE; Gold JA; Tamura RN; Driscoll DJ; Butler MG; Kimonis VE
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neural correlates of self-injurious behavior in Prader-Willi syndrome.
    Klabunde M; Saggar M; Hustyi KM; Hammond JL; Reiss AL; Hall SS
    Hum Brain Mapp; 2015 Oct; 36(10):4135-43. PubMed ID: 26173182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin Picking in People with Prader-Willi Syndrome: Phenomenology and Management.
    Bull LE; Oliver C; Woodcock KA
    J Autism Dev Disord; 2021 Jan; 51(1):286-297. PubMed ID: 32495267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
    Selikowitz M; Sunman J; Pendergast A; Wright S
    Arch Dis Child; 1990 Jan; 65(1):112-4. PubMed ID: 2405783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compulsive behavior and eye blink in Prader-Willi syndrome: neurochemical implications.
    Holsen L; Thompson T
    Am J Ment Retard; 2004 May; 109(3):197-207. PubMed ID: 15072522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prader-Willi and bipolar illness.
    Jerome L
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):876-7. PubMed ID: 8340315
    [No Abstract]   [Full Text] [Related]  

  • 31. Fluoxetine for serotonin reuptake inhibitor discontinuation syndrome.
    Benazzi F
    J Psychiatry Neurosci; 1998 Sep; 23(4):241-2. PubMed ID: 9785704
    [No Abstract]   [Full Text] [Related]  

  • 32. Fluoxetine for OCD after brain injury.
    Stengler-Wenzke K; Müller U
    Am J Psychiatry; 2002 May; 159(5):872. PubMed ID: 11986149
    [No Abstract]   [Full Text] [Related]  

  • 33. Fluoxetine: therapeutic and undesirable effects.
    Cookson J; Duffett R
    Hosp Med; 1998 Aug; 59(8):622-6. PubMed ID: 9829055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome.
    Miller JL; Angulo M
    Am J Med Genet A; 2014 Feb; 164A(2):421-4. PubMed ID: 24311388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The latent variable structure of the Compulsive Behaviour Checklist in people with Prader-Willi syndrome.
    Feurer ID; Dimitropoulos A; Stone WL; Roof E; Butler MG; Thompson T
    J Intellect Disabil Res; 1998 Dec; 42 ( Pt 6)(Pt 6):472-80. PubMed ID: 10030443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment.
    Soni S; Whittington J; Holland AJ; Webb T; Maina E; Boer H; Clarke D
    J Intellect Disabil Res; 2007 Jan; 51(Pt 1):32-42. PubMed ID: 17181601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoxetine in the treatment of self-mutilating behavior.
    Velazquez L; Ward-Chene L; Loosigian SR
    J Am Acad Child Adolesc Psychiatry; 2000 Jul; 39(7):812-4. PubMed ID: 10892222
    [No Abstract]   [Full Text] [Related]  

  • 38. Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: a case for looking beyond serotonin.
    Zurowski B; Wahl K; Hohagen F; Kordon A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):959-60. PubMed ID: 17321024
    [No Abstract]   [Full Text] [Related]  

  • 39. [Self-induced cutaneous lesions in Prader-Willi syndrome].
    Plantin P; Milochau P; Broussine L; Blondin G
    Ann Dermatol Venereol; 1997; 124(5):390-2. PubMed ID: 9739896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study.
    Singh D; Wakimoto Y; Filangieri C; Pinkhasov A; Angulo M
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):313-317. PubMed ID: 30724590
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.